These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38478102)
41. Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer. Tan WP; Kotamarti S; Ayala A; Mahle R; Chen E; Arcot R; Chang A; Michael Z; Seguier D; Polascik TJ Eur Urol Oncol; 2023 Jun; 6(3):289-294. PubMed ID: 36890104 [TBL] [Abstract][Full Text] [Related]
42. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer. Miszczyk M; Magrowski Ł; Masri O; Jabłon'ska I; Nowicka Z; Krzysztofiak T; Wojcieszek P; Lipka-Rajwa A; Ciepał J; Depowska G; Chimiak K; Bylica G; Płoszka K; Łaszczych M; Majewski W J Contemp Brachytherapy; 2022 Feb; 14(1):15-22. PubMed ID: 35233230 [TBL] [Abstract][Full Text] [Related]
43. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy. Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753 [TBL] [Abstract][Full Text] [Related]
44. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537 [TBL] [Abstract][Full Text] [Related]
45. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel. Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598 [TBL] [Abstract][Full Text] [Related]
46. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768 [TBL] [Abstract][Full Text] [Related]
47. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455 [TBL] [Abstract][Full Text] [Related]
48. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Knipper S; Ascalone L; Ziegler B; Hohenhorst JL; Simon R; Berliner C; van Leeuwen FWB; van der Poel H; Giesel F; Graefen M; Eiber M; Heck MM; Horn T; Maurer T Eur Urol; 2021 Apr; 79(4):537-544. PubMed ID: 33317857 [TBL] [Abstract][Full Text] [Related]
49. Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer. Kvorning Ternov K; Krag Jakobsen A; Bratt O; Ahlgren G Scand J Urol; 2015 Apr; 49(2):115-9. PubMed ID: 25428754 [TBL] [Abstract][Full Text] [Related]
50. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288 [TBL] [Abstract][Full Text] [Related]
51. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170 [TBL] [Abstract][Full Text] [Related]
52. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034 [TBL] [Abstract][Full Text] [Related]
53. Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data. Spiess PE; Given RW; Jones JS BJU Int; 2012 Jul; 110(2):217-20. PubMed ID: 21992443 [TBL] [Abstract][Full Text] [Related]
55. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. Spiess PE; Levy DA; Pisters LL; Mouraviev V; Jones JS World J Urol; 2013 Dec; 31(6):1321-5. PubMed ID: 23179729 [TBL] [Abstract][Full Text] [Related]
56. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
57. Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience. Tan WP; Kotamarti S; Chen E; Mahle R; Arcot R; Chang A; Ayala A; Michael Z; Seguier D; Polascik TJ Cancer; 2022 Nov; 128(21):3824-3830. PubMed ID: 36107496 [TBL] [Abstract][Full Text] [Related]
58. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Wenske S; Quarrier S; Katz AE Eur Urol; 2013 Jul; 64(1):1-7. PubMed ID: 22840351 [TBL] [Abstract][Full Text] [Related]
59. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436 [TBL] [Abstract][Full Text] [Related]
60. Oncologic outcomes at 10 years following robotic radical prostatectomy. Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]